Comparative evaluation of five immunoassays for the analysis of Alprazolam and Triazolam metabolites in urine: Effect of lowering the screening and GC-MS cut-off values

Journal of Analytical Toxicology

Volumn 20, Issue 4, 1996, Pages 217-223

  Fraser, Albert D ^a   Meatherall, Robert ^b  

^a QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^b ST BONIFACE GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; BENZODIAZEPINE DERIVATIVE; DRUG METABOLITE; TRIAZOLAM;

ARTICLE; DRUG DETERMINATION; DRUG HYDROLYSIS; DRUG URINE LEVEL; GAS CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; IMMUNOASSAY; MASS SPECTROMETRY; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; QUANTITATIVE ASSAY; URINALYSIS;

EID: 0029889163     PISSN: 01464760     EISSN: None     Source Type: Journal    
DOI: 10.1093/jat/20.4.217     Document Type: Article

References (23)

1. U.E. Busto, K.L. Lanctôt, K.E. Bremner, and E.M. Sellers. Benzodiazepine kinetics contribute to their differential abuse. Can. J. Clin. Pharmacol. 2: 23-28 (1995).
2. G.K. Munford, S.M. Evans, J.C. Fleishaker, and R.R. Griffiths. Alprazolam absorption kinetics affects abuse liability. Clin. Pharmacol. Ther. 57: 356-65 (1995).
3. R.P. Baker, E.L. Gurwich, and M.S. Cohon. Alprazolam pharmacokinetic profile. The Upjohn Company, Kalamazoo, MI, March 1985.
4. E.L. Gurwich, J.P. Olree, and E.S. Cohon. Triazolam human pharmacokinetic review. The Upjohn Company, Kalamazoo, MI, November 1985.
5. K.F. Buechler, S. Moi, B. Noar, D. McGrath, J. Villela, M. Clancy, A. Shenhav, A. Colleymore, G. Valkirs, T. Lee, J.F. Bruni, M. Walsh, R. Hoffman, F. Ahmuty, M. Nowakowski, J. Buechler, M. Mitchell, D. Boyd, N. Stiso, and R. Anderson. Simultaneous detection of seven drugs of abuse by the Triage™ panel for drugs of abuse. Clin. Chem. 38: 1678-84 (1992).
6. L.E. Edinboro and A. Poklis. Detection of benzodiazepines and tribenzazolams by TRIAGE™ : confirmation by solid-phase extraction utilizing SPEC®•3ML•MP3 microcolumns and GC-MS. J. Anal. Toxicol. 18: 312-16 (1994).
7. R.L. Fitzgerald, D.A. Rexin, and D.A. Herold. Detecting benzodiazepines: immunoassays compared with negative chemical ionization gas chromatography/mass spectrometry. Clin. Chem. 40: 373-80 (1994).
8. T.R. Koch, R.L. Raglin, S. Kirk, and J.F. Bruni. Improved screening for benzodiazepine metabolites in urine using the TRIAGE™ panel for drugs of abuse. J. Anal. Toxicol. 18: 168-72 (1994).
9. A.D. Fraser, W. Bryan, and A.F. Isner. Urinary screening for α-OH-triazolam by FPIA and EIA with confirmation by GC/MS. J. Anal. Toxicol. 16: 347-50 (1992).
10. A.D. Fraser, W. Bryan, and A.F. Isner. Urinary screening for alprazolam and its major metabolites by the Abbott ADx and TDx analyzers with confirmation by GC/MS. J. Anal. Toxicol. 15: 25-29 (1991).
11. G. Asselborn and R. Wennig. Evaluation of the new immunoassay "TRIAGE". Proceedings of the 30th International Meeting of TIAFT, Fukuoka, Japan, 150-53 (1992).
12. H. Käferstein, G. Stricht, and R. Iffland. Experience with the new immunoassay TRIAGE. Proceedings of the 30th International Meeting of TIAFT, Fukuoka, Japan, 154-57 (1992).
13. A.H.B. Wu, E. Forte, G. Casella, K. Sun, G. Hemphill, R. Foery, and H. Schanzenbach. CEDIA for screening drugs of abuse in urine and the effect of adulterants. J. Forensic Sci. 40: 614-18 (1995).
14. A.D. Fraser. Urinary screening for alprazolam, triazolam and their metabolites with the EMIT® d.a.u.™ benzodiazepine metabolite assay. J. Anal. Toxicol. 11:263-66 (1987).
15. W. Huang, D.E. Moody, D.M. Andrenyak, and D.E. Rollins. Immunoassay detection of nordiazepam, triazolam, lorazepam, and alprazolam in blood. J. Anal. Toxicol. 17: 365-69 (1993).
16. W. Huang and D.E. Moody. Immunoassay detection of benzodiazepines and benzodiazepine metabolites in blood. J. Anal. Toxicol. 19: 333-42 (1995).
17. O. Beck, P. Lafolie, G. Odelius, and L. Boreus. Immunological screening of benzodiazepines in urine: improved detection of oxazepam intake. Toxicol. Lett. 52: 7-14 (1990).
18. R. Meatherall. Optimal enzymatic hydrolysis of urinary benzodiazepine conjugates. J. Anal. Toxicol. 18: 382-84 (1994).
19. R. Meatherall. Benzodiazepine screening using EMIT II® and TDx®: Urine hydrolysis pretreatment required. J. Anal. Toxicol. 18: 385-90 (1994).
20. P. Simonsson, A. Lidén, and S. Lindberg. Effect of β-glucuronidase on urinary benzodiazepine concentrations determined by fluorescence polarization immunoassay. Clin. Chem. 41: 920-23 (1995).
21. R. Meatherall. GC-MS confirmation of urinary benzodiazepine metabolites. J. Anal. Toxicol. 18: 369-81 (1994).
22. Bio-Site Diagnostics TRIAGE Panel for drugs of abuse specificity table. Bio-Site Diagnostics, San Diego, CA, September 1994.
23. R.L. Boeckx. User modification of commercial immunoassay kits. Clin. Chem. 38: 1402-1403 (1992).